Immune-checkpoint inhibitors (ICIs) such as programmed cell death (PD-1) and its ligand (PD-L1), which act by reversing immunosuppression have recently been shown to be effective in the treatment of HCC (Inarrairaegui et al., 2018). Here, CD274 is linked to hepatocellular carcinoma.